clinical trial · NCT05521438

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

$QNRX →·phase3·active not recruiting·n = 30

Netherton SyndromeQRX003-2% LotionQRX003-4% Lotion QAMVehicleQRX003-4% Lotion BID

brief summary

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle

started

Jun 23, 2022

primary completion

Dec 30, 2025

completion

Dec 31, 2026

last updated

Mar 16, 2026

official title

A Multicenter, Randomized, Vehicle-Controlled, Double-Blind, Parallel Comparison Study of QRX003 Lotion in Subjects With Netherton Syndrome

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol